BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
Excerpt from the Press Release:
HOPEWELL, N.J. & CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support, a 501(c)(3) organization committed to transforming the cancer experience for patients and their families across New Jersey, today announced a grant from BeiGene that will enable Crossroads4Hope to expand the reach of its psychosocial support programs to more vulnerable patients and communities.
“As BeiGene expands its presence in the New Jersey business community with our new site to be built in Hopewell, we are committed to joining with organizations that are deeply engaged in the New Jersey cancer community, as is Crossroads4Hope,” said Shreya Jani, Vice President of Corporate Affairs at BeiGene. “Crossroads4Hope’s founding belief that all those affected by cancer should have a safe place to turn for emotional and social support, and their commitment to reaching the most vulnerable communities, align well with BeiGene’s vision to change how cancer is treated by developing impactful medicines that will be affordable and accessible to far more cancer patients.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?